Griffithsin protects mice from genital herpes by preventing cell-to-cell spread

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6257-6269

  Nixon, Briana ^a   Stefanidou, Martha ^a   Mesquita, Pedro M M ^a   Fakioglu, Esra ^a   Segarra, Theodore ^a   Rohan, Lisa ^b   Halford, William ^c   Palmer, Kenneth E ^d,e   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^e Owensboro Cancer Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GRIFFITHSIN; LECTIN; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL SPREADING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ELECTRIC RESISTANCE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCORING SYSTEM; SEMINAL PLASMA; SINGLE DRUG DOSE; SURVIVAL TIME; VIRUS ENTRY; VIRUS PLAQUE; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; PLANT LECTINS; VIRUS INTERNALIZATION;

EID: 84878210806     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00012-13     Document Type: Article

References (56)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. MTN.25 November 2011, posting date. MTN statement on decision to discontinue tenofovir gel in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3909. MTN, Pittsburgh, PA.
3. MTN. 28 September 2011, posting date. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3619. MTN, Pittsburgh, PA.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410.
5. Celum C, Baeten JM. 2012. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr. Opin. Infect. Dis. 25:51-57.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC,Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-422.
7. Kiser PF, Mesquita PM, Herold BC. 2012. A perspective on progress and gaps in HIV prevention science. AIDS Res. Hum. Retroviruses 28:1373-1378.
8. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L. 2010. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, griffithsin, cyanovirin-N and scytovirin. Virology 402:187-196.
9. Emau P, Tian B, O'Keefe RB, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC. 2007. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36:244-253.
10. Ferir G, Palmer KE, Schols D. 2011. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417:253-258.
11. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
12. Hurt CB, Eron JJ, Jr, Cohen MS. 2011. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin. Infect. Dis. 53: 1265-1270.
13. Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, Walter W, Walker JM, Matoba N, O'Keefe BR, Palmer KE. 2011. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 6:e22635. doi:10.1371/journal.pone.0022635.
14. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC. 2009. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J. Infect. Dis. 200:599-608.
15. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC. 2007. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J. Infect. Dis. 195:1332-1339.
16. Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, Doncel GF, Herold BC. 2011. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One 6:e27675. doi:10.1371/journal.pone .0027675.
17. Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, Herold BC. 2009. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir. Ther. 14:1113-1124.
18. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359:463-472.
19. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR. 2003. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47:2518-2525.
20. Tiwari V, Shukla SY, Shukla D. 2009. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antiviral Res. 84:67-75.
21. Balzarini J. 2007. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5:583-597.
22. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6:e23521. doi:10.1371/journal.pone.0023521.
23. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107:13800-13805.
24. Wenske EA, Bratton MW, Courtney RJ. 1982. Endo-beta-N-acetylglucosaminidaseHsensitivity of precursors to herpes simplex virus type 1 glycoproteins gB and gC. J. Virol. 44:241-248.
25. Fichorova RN, Rheinwald JG, Anderson DJ. 1997. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissuespecific differentiation proteins. Biol. Reprod. 57:847-855.
26. Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC. 2007. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J. Virol. 81:7636-7646.
27. Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ. 2008. Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J. Virol. 82:6576-6584.
28. Stefanidou M, Ramos I, Mas Casullo V, Trepanier JB, Rosenbaum S, Fernandez-Sesma A, Herold BC. 2013. HSV-2 prevents dendritic cell maturation, induces apoptosis and triggers release of pro-inflammatory cytokines: potential links to HSV-HIV synergy. J. Virol. 87:1443-1453.
29. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J. Gen. Virol. 2:357-364.
30. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. 2011. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6:e17748. doi:10.1371/journal.pone.0017748.
31. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 48:2025-2036.
32. Hendrickson BA, Guo J, Brown I, Dennis K, Marcellino D, Hetzel J, Herold BC. 2000. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Virology 271:155-162.
33. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC. 2010. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 5:e8781. doi:10.1371/journal.pone.0008781.
34. Keller MJ, Madan RP, Shust G, Carpenter CA, Torres NM, Cho S, Khine H, Huang ML, Corey L, Kim M, Herold BC. 2012. Changes in the soluble mucosal immune environment during genital herpes outbreaks. J. Acquir. Immune Defic. Syndr. 61:194-202.
35. Peng T, Zhu J, Klock A, Phasouk K, Huang ML, Koelle DM, Wald A, Corey L. 2009. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J. Virol. 83:12559-12568.
36. Singh R, Kumar A, Creery WD, Ruben M, Giulivi A, Diaz-Mitoma F. 2003. Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection. Clin. Exp. Immunol. 133: 97-107.
37. Collins SE, Noyce RS, Mossman KL. 2004. Innate cellular response to virus particle entry requires IRF3 but not virus replication. J. Virol. 78: 1706-1717.
38. Rasmussen SB, Sorensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, Paludan SR. 2007. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 81:13315-13324.
39. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. 2010. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376:1329-1337.
40. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ. 2007. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 196:1394-1402.
41. Rauch DA, Rodriguez N, Roller RJ. 2000. Mutations in herpes simplex virus glycoproteinDdistinguish entry of free virus from cell-cell spread. J. Virol. 74:11437-11446.
42. Polcicova K, Goldsmith K, Rainish BL, Wisner TW, Johnson DC. 2005.The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE/gI receptors. J. Virol. 79: 11990-12001.
43. Saldanha CE, Lubinski J, Martin C, Nagashunmugam T, Wang L, van Der Keyl H, Tal-Singer R, Friedman HM. 2000. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease. J. Virol. 74:6712-6719.
44. Serafini-Cessi F, Dall'Olio F, Scannavini M, Campadelli-Fiume G. 1983. Processing of herpes simplex virus-1 glycans in cells defective in glycosyl transferases of the Golgi system: relationship to cell fusion and virion egress. Virology 131:59-70.
45. Selhorst P, Grupping K, Bourlet T, Delezay O, Arien KK, Vanham G. 2012. In vitro activities of candidate microbicides against cell-associated HIV. Antimicrob. Agents Chemother. 56:805-815.
46. Biller M, Mardberg K, Hassan H, Clausen H, Bolmstedt A, Bergstrom T, Olofsson S. 2000. Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties. Glycobiology 10:1259-1269.
47. Herold BC, WuDunn D, Soltys N, Spear PG. 1991. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J. Virol. 65:1090-1098.
48. Gerber SI, Belval BJ, Herold BC. 1995. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology 214:29-39.
49. Herold BC, Gerber SI, Polonsky T, Belval BJ, Shaklee PN, Holme K. 1995. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. Virology 206:1108-1116.
50. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, Defer MC, Djagbare D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P. 2007. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356:790-799.
51. Chen L, Jha P, Stirling B, Sgaier SK, Daid T, Kaul R, Nagelkerke N. 2007. Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS One 2:e1001. doi:10.1371/journal.pone.0001001.
52. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
53. O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB, Jr. 2010. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84:2511-2521.
54. Moulaei T, Shenoy SR, Giomarelli B, Thomas C, McMahon JB, Dauter Z, O'Keefe BR, Wlodawer A. 2010. Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. Structure 18:1104-1115.
55. Ziolkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, Wormald MR, Wlodawer A. 2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins 67:661-670.
56. Hansen JE, Nielsen C, Vestergaard BF. 1991. Inhibition of human immunodeficiency virus 1 (HIV-1) and herpes simplex virus 1 (HSV-1) infectivity with a broad range of lectins. Scand. J. Infect. Dis. 23:425-430.